Jennifer Cooperrider

Jennifer Cooperrider is an Assistant Professor in the Department of Medicine-Hematology and Oncology at the University of Chicago's Pritzker School of Medicine. Her research focuses on hematological malignancies, particularly multiple myeloma and acute myeloid leukemia.

Dr. Cooperrider's research interests include:

• Multiple Myeloma treatment strategies and outcomes
• CAR T-cell therapy and associated toxicities
• Measurable residual disease assessment
• Hematopoietic stem cell transplantation
• Novel therapeutic approaches for hematological malignancies
• Timing optimization for cellular therapies

Her recent work demonstrates significant contributions to understanding treatment protocols for multiple myeloma, particularly in the areas of CAR T-cell therapy timing, bridging treatments, and maintenance therapy discontinuation guided by measurable residual disease status. She has also made important contributions to the understanding of acute myeloid leukemia treatment strategies and has explored pharmacoeconomic aspects of oncology treatment in international settings.

Dr. Cooperrider actively collaborates with prominent researchers in the field including Benjamin Derman, Andrzej Jakubowiak, Michael Bishop, and Satyajit Kosuri, as evidenced by her publication record across high-impact journals such as Blood, Blood Cancer Journal, and JCO Oncology Practice.